Logo Medical Science Monitor

Call: +1.631.470.9640
Mon - Fri 10:00 am - 02:00 pm EST

Contact Us

Logo Medical Science Monitor Logo Medical Science Monitor Logo Medical Science Monitor

01 April 2011

Access to biologic treatment for rheumatoid arthritis in Central and Eastern European (CEE) countries

Ewa OrlewskaABCDEFG, Ioan AncutaB, Branimir AnicB, Catalin CodrenauB, Nemanja DamjanovB, Predrag DjukicB, Ruxandra IonescuB, Lubomir MarinchevB, Evgeny L. NasonovB, Tonu PeetsB, Sonja PraprotnikB, Rasho RashkovB, Jana SkoupaB, Witold TlustochowiczB, Malgorzata TlustochowiczB, Matija TomsicB, Tiina VeldiB, Jelena VojinovicB, Piotr WilandB

DOI: 10.12659/MSM.881697

Med Sci Monit 2011; 17(4): SR1-13

Abstract

Background: The aim of this study was to assess and compare patients’ access to biologic anti-RA drugs in selected Central and Eastern European (CEE) countries and to analyze the determinants of differences between countries.
Material/Methods: This is a multi-country survey study, based on a combination of desk research and direct contact with national RA stakeholders. Data was collected using a pre-defined questionnaire. Affordability was measured using an affordability index, calculated comparing the index of health care expenditures to the price index, using Poland as an index of 1.
Results: The percentage of patients on biologic treatment in 2009 was highest in Hungary (5% RA patients on biologic treatment), followed by Slovenia (4.5%), Slovakia (3.5%), Czech Republic (2.92%), Romania (2.2%), Estonia (1.8%), and Croatia, Serbia, Poland (below 1.5%). Infliximab, etanercept, adalimumab and rituximab were included in the reimbursement system in all countries, but abatacept and tocilizumab were included only in Slovakia. In Slovenia, public payer covered 75% of the price, and 25% is covered by supplementary health insurance; in Bulgaria public payer covered 50% of etanercept and adalimumab costs, and 75% of rituximab cost. In other countries, biologic drugs are reimbursed at 100%. Affordability index for biologic drugs was the lowest in Slovenia (0.4). In each country national guidelines define which patients are eligible for biologic treatment. Disease Activity Score (DAS28) of over 5.1 and failure of 2 or more disease-modifying anti-RA drugs, including methotrexate, are commonly used criteria.
Conclusions: The most important factors limiting access to biologic anti-RA treatment in the CEE region are macroeconomic conditions and restrictive treatment guidelines.

Keywords: Europe, Health Expenditures, Delivery of Health Care - economics, Costs and Cost Analysis, Biological Therapy, Arthritis, Rheumatoid - therapy, Antirheumatic Agents - therapeutic use, Health Planning Guidelines, Health Services Accessibility - economics

0 Comments

Editorial

04 June 2022 : Editorial  

Editorial: Acute Hepatitis of Unknown Origin in Children. Is Autoimmunity at Play?

Nahum Mendez-Sanchez, Shreya C. Pal
Faculty of Medicine, National Autonomous University of Mexico, Mexico City, Mexico

DOI: 10.12659/MSM.937371

Med Sci Monit 2022; 28:e937371

In Press

27 Jun 2022 : Clinical Research  

Automatic Identification of Depression Using Facial Images with Deep Convolutional Neural Network

Med Sci Monit In Press; DOI: 10.12659/MSM.936409  

23 Jun 2022 : Clinical Research  

A Real-World Study to Compare the Safety and Efficacy of Paritaprevir/Ombitasvir/Ritonavir and Dasabuvir, w...

Med Sci Monit In Press; DOI: 10.12659/MSM.936706  

22 Jun 2022 : Clinical Research  

A Single-Center Study Comparing the Effects of Thoracic Spine Manipulation vs Mobility Exercises in 26 Offi...

Med Sci Monit In Press; DOI: 10.12659/MSM.937316  

21 Jun 2022 : Clinical Research  

Optimal Timing and Outcomes of Minimally Invasive Approach in Acute Biliary Pancreatitis

Med Sci Monit In Press; DOI: 10.12659/MSM.937016  

Most Viewed Current Articles

30 Dec 2021 : Clinical Research  

Retrospective Study of Outcomes and Hospitalization Rates of Patients in Italy with a Confirmed Diagnosis o...

DOI :10.12659/MSM.935379

Med Sci Monit 2021; 27:e935379

08 Mar 2022 : Review article  

A Review of the Potential Roles of Antioxidant and Anti-Inflammatory Pharmacological Approaches for the Man...

DOI :10.12659/MSM.936292

Med Sci Monit 2022; 28:e936292

01 Nov 2020 : Review article  

Long-Term Respiratory and Neurological Sequelae of COVID-19

DOI :10.12659/MSM.928996

Med Sci Monit 2020; 26:e928996

01 Jan 2022 : Editorial  

Editorial: Current Status of Oral Antiviral Drug Treatments for SARS-CoV-2 Infection in Non-Hospitalized Pa...

DOI :10.12659/MSM.935952

Med Sci Monit 2022; 28:e935952

Your Privacy

We use cookies to ensure the functionality of our website, to personalize content and advertising, to provide social media features, and to analyze our traffic. If you allow us to do so, we also inform our social media, advertising and analysis partners about your use of our website, You can decise for yourself which categories you you want to deny or allow. Please note that based on your settings not all functionalities of the site are available. View our privacy policy.

Medical Science Monitor eISSN: 1643-3750
Medical Science Monitor eISSN: 1643-3750